Patient-Derived Gastrointestinal Cancer Organoid Model

Gastrointestinal cancers, including gastric, hepatic, esophageal, pancreatic, and colorectal, account for one-fourth of the global cancer incidence and one-third of cancer-related deaths. Creative Biolabs understands your gastrointestinal cancer research needs and is your trustworthy partner for the mechanism research on gastrointestinal cancer and the drug development of preclinical stages.

Construction of Patient-derived Gastrointestinal Cancer Organoid Models

Recently developed 3D culture systems termed organoids open up new opportunities in cancer research, including efforts to personalize cancer treatment. The preparation methods differ depending on the tissue and stem cell type. The general process is as follows: after resection or biopsy, the tissue is either digested to release the crypts (for the esophagus, stomach, and intestinal tissue) or until single cells or cell clusters are left. These are subsequently plated in a basement membrane extract and overlaid with an organoid growth medium.

Fig.1 Organoids can be made from resected healthy or tumour material, or from biopsies. (Aberle, 2021)

Advantages of Patient-derived Gastrointestinal Cancer Organoid Models

Patient-derived gastrointestinal cancer organoids are self-organizing, 3-dimensional cultures derived from primary or metastatic gastrointestinal tumor tissues. Compared with traditional models such as cell lines, genetically engineered mouse models, and patient-derived xenografts (PDXs). Gastrointestinal patient-derived organoid (PDO) models have exhibited particular advantages.

• Retain the heterogeneity and genetic identity of the cancer tissue from which they are derived.
• Serve as patient-specific “avatars” that can is accomplished in a short time (weeks), often with high efficiency, and cultures can usually be passaged an unlimited number of times.
• Show a more significant expansion capacity, including the expansion of low-frequency cell populations that may contribute to tumorigenesis, making them ideal for studying drug sensitivity.
• Much cheaper than mouse-based PDX models.
• Emerging evidence from a retrospective analysis of a few patients showed that PDO responses to chemotherapeutic agents are concordant with the initial responses of PDO donor patients to the same agents.

Applications

Gastrointestinal PDOs have also been described for numerous types of human gastrointestinal cancers. To date, PDO biobanks have been established within the gastrointestinal tract for colorectal cancer (CRC) and gastric cancers, including esophageal adenocarcinoma (GC/EAC), esophageal squamous cell carcinoma (ESCC), liver cancer (LC), pancreatic ductal adenocarcinoma (PDAC), and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Such preclinical tumor models serve as essential tools for studying cancer biology, developing novel therapeutics, and informing treatment decisions and have rich applications in cancer research.

Fig.2 Applications of cancer organoids in cancer research. (Seidlitz, 2021)

Related Services

Creative Biolabs is a global leader in providing 3D organoid models to researchers focused on life sciences and pharmaceuticals. We are committed to providing the highest quality patient-derived gastrointestinal cancer organoid model and related services listed below to facilitate the progress of your drug discovery projects. Don’t hesitate to contact us to discuss your project for professional assistance.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model